Advertisement Bruker Q2 Revenues Up 19% - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bruker Q2 Revenues Up 19%

Bruker, a provider of scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis, has reported revenues of $300.9m for the second quarter ended June 30, 2010, an increase of 19%, compared to $252.5m for the comparable period in 2009.

Bruker has posted a net income of $22.6m for the second quarter 2010, or $0.14 per diluted share, compared to net income of $12.9, or $0.08 per diluted share, for the comparable period in 2009. Operating income was $37.9m, compared to $20.2m for the comparable period in 2009.

For the six months ended June 30, 2010, Bruker has posted revenue of $578.6m compared to $483m for the year ago period. Operating income was $64.8m, compared to $34.5m for the year ago period.

Bruker has posted a net income of $38.7m, or $0.23 per diluted share for six months ended June 30, 2010, compared to $21.3m, or $0.13 per diluted share, for the year ago period.

Frank Laukien, president and CEO of Bruker, said: “We are extremely pleased with both our second quarter and half year results, with record first half revenues, operating income and earnings per share.

“For the second quarter in a row all four operating divisions in our Scientific Instruments segment delivered double-digit organic growth year-over-year.

“We monitor academic and government research budgets in Europe, and we believe that overall these will continue to be stable or growing.”